Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

NCT00418379 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

633

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: 300 IR (4M)
DRUG: 300 IR (2M)
DRUG: Placebo

Sponsor

Stallergenes Greer